Ankylosing Spondylitis (Bekhterev’s Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine’s bones (vertebrae) may grow or fuse together, resulting in a rigid spine.
The Ankylosing Spondylitis pipeline drugs market research report provides comprehensive information on the therapeutics under development for ankylosing spondylitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.
Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Targets
The key targets of the ankylosing spondylitis pipeline drugs market are Tumor Necrosis Factor, Interleukin 17A, Lymphotoxin Alpha, Tyrosine Protein Kinase JAK1, Interleukin 17F, Interleukin 17, MAP Kinase Activated Protein Kinase 2, Mitogen Activated Protein Kinase 1, and Granulocyte Macrophage Colony Stimulating Factor. Tumor Necrosis Factor is the target with the highest number of ankylosing spondylitis pipeline drugs in development in 2022.
Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Targets
For more target insights into the ankylosing spondylitis pipeline drugs market, download a free report sample
Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action of the ankylosing spondylitis pipeline drugs market are Tumor Necrosis Factor Inhibitor, Interleukin 17A Inhibitor, Lymphotoxin Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 17 Inhibitor, Interleukin 17F Inhibitor, and MAP Kinase Activated Protein Kinase 2 Inhibitor. The Tumor Necrosis Factor Inhibitor MoA has the highest number of ankylosing spondylitis pipeline drugs in development in 2022.
Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the ankylosing spondylitis pipeline drugs market, download a free report sample
Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the ankylosing spondylitis pipeline drugs market are subcutaneous, intravenous, oral, parenteral, and topical. Subcutaneous was the most common RoA for ankylosing spondylitis pipeline drugs in development in 2022.
Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the ankylosing spondylitis pipeline drugs market, download a free report sample
Ankylosing Spondylitis Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the ankylosing spondylitis pipeline drugs market are monoclonal antibody, small molecule, fusion protein, protein, small molecule, synthetic peptide, and others. Monoclonal antibody is the most common molecule type for ankylosing spondylitis pipeline drugs in development in 2022.
Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the ankylosing spondylitis pipeline drugs market, download a free report sample
Ankylosing Spondylitis Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the ankylosing spondylitis pipeline drugs market are Avesthagen Ltd, Biocad, Bioviz Technologies Pvt Ltd, Bristol-Myers Squibb Co, DNX Biopharmaceuticals Inc, Immunwork Inc, and Mabpharm Ltd.
Ankylosing Spondylitis Pipeline Drugs Market Analysis, by Companies
To know more about the companies in the ankylosing spondylitis pipeline drugs market, download a free report sample
Ankylosing Spondylitis Pipeline Drugs Market Report Overview
Key Targets | Tumor Necrosis Factor, Interleukin 17A, Lymphotoxin Alpha, Tyrosine Protein Kinase JAK1, Interleukin 17F, Interleukin 17, MAP Kinase Activated Protein Kinase 2, Mitogen Activated Protein Kinase 1, and Granulocyte Macrophage Colony Stimulating Factor |
Key Mechanisms of Action | Tumor Necrosis Factor Inhibitor, Interleukin 17A Inhibitor, Lymphotoxin Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 17 Inhibitor, Interleukin 17F Inhibitor, and MAP Kinase Activated Protein Kinase 2 Inhibitor |
Key Routes of Administration | Subcutaneous, Intravenous, Oral, Parenteral, and Topical |
Key Molecule Types | Monoclonal Antibody, Small Molecule, Fusion Protein, Protein, Small Molecule, Synthetic Peptide, and Others |
Leading Companies | Avesthagen Ltd, Biocad, Bioviz Technologies Pvt Ltd, Bristol-Myers Squibb Co, DNX Biopharmaceuticals Inc, Immunwork Inc, and Mabpharm Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev’s Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AbbVie Inc
Akeso Inc
AstraZeneca Plc
Avesthagen Ltd
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
Biocad
Biogen Inc
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Celltrion Inc
Clover Biopharmaceuticals Ltd
DNX Biopharmaceuticals Inc
Dyadic International Inc
Eli Lilly and Co
Enzene Biosciences Ltd
Foshan Rexie Biotechnology Co Ltd
FunPep Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Hualan Biological Engineering Inc
Iltoo Pharma
Immunwork Inc
Izana Bioscience Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
Livzon Pharmaceutical Group Co Ltd
Luye Pharma Group Ltd
Lynk Pharmaceutical Hangzhou Co Ltd
Mabpharm Ltd
MoonLake Immunotherapeutics
Mycenax Biotech Inc
NeuClone Pty Ltd
Nimbus Therapeutics LLC
North China Pharmaceutical Group New Drug Research and Development Co Ltd
Novartis AG
Outlook Therapeutics Inc
Pharmapraxis
PKU V-Ming (Hefei) Biologics Co Ltd
Qilu Pharmaceutical Co Ltd
Sandoz International GmbH
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Siam Bioscience Co Ltd
SinoCelltech Group Ltd
siRNAgen Therapeutics Corp
Suzhou Zelgen Biopharmaceutical Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
UCB SA
Valin Technologies Ltd
Wuhan Institute of Biological Products Co Ltd
XinThera Inc
Zhejiang Yatai Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the ankylosing spondylitis pipeline drugs market?
The key targets of the ankylosing spondylitis pipeline drugs market are Tumor Necrosis Factor, Interleukin 17A, Lymphotoxin Alpha, Tyrosine Protein Kinase JAK1, Interleukin 17F, Interleukin 17, MAP Kinase Activated Protein Kinase 2, Mitogen Activated Protein Kinase 1, and Granulocyte Macrophage Colony Stimulating Factor.
-
What are the key mechanisms of action of the ankylosing spondylitis pipeline drugs market?
The key mechanisms of action of the ankylosing spondylitis pipeline drugs market are Tumor Necrosis Factor Inhibitor, Interleukin 17A Inhibitor, Lymphotoxin Alpha Inhibitor, Tyrosine Protein Kinase JAK1 Inhibitor, Interleukin 17 Inhibitor, Interleukin 17F Inhibitor, and MAP Kinase Activated Protein Kinase 2 Inhibitor.
-
What are the key routes of administration in the ankylosing spondylitis pipeline drugs market?
The key routes of administration in the ankylosing spondylitis pipeline drugs market are subcutaneous, intravenous, oral, parenteral, and topical.
-
What are the key molecule types in the ankylosing spondylitis pipeline drugs market?
The molecule types in the ankylosing spondylitis pipeline drugs market are monoclonal antibody, small molecule, fusion protein, protein, small molecule, synthetic peptide, and others.
-
Which are the leading companies in the ankylosing spondylitis pipeline drugs market?
Some of the leading companies in the ankylosing spondylitis pipeline drugs market are Avesthagen Ltd, Biocad, Bioviz Technologies Pvt Ltd, Bristol-Myers Squibb Co, DNX Biopharmaceuticals Inc, Immunwork Inc, and Mabpharm Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.